MTAP and chordoma: Recently, molecular features that could indicate the application of targeted therapies have been identified in chordoma, including activation of the PI3K/Akt/mTOR pathway [8], activation of the IGF1R signaling cascade [9], loss of methylthioadenosine phosphorylase [9], and activation of STAT3 [10].